Immunomedics submits additional CEA-Scan data
This article was originally published in Clinica
Executive Summary
Immunomedics (US) claims that its CEA-Scan colorectal imaging agent provides clinically useful information for pre-surgical evaluation of recurrent cancer patients. Results were derived from Phase III trials in response to the US FDA's request for additional information after the agency found the agent not approvable last year (see Clinica No 605, p 26). Immunomedics has submitted the additional data to the FDA.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.